StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Merck (MRK) PT Raised to $90 at Morgan Stanley on Gardasil Strength
October 29, 2021 8:46 AM
Morgan Stanley analyst Matthew Harrison raised the price target on Merck (NYSE: MRK) to $90.00 (from $88.00) while maintaining a ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS Change
Analyst EPS View
Analyst PT Change
Next Articles
Merck (MRK) PT Raised to $86 at BofA Securities
October 29, 2021 8:24 AM
Merck (MRK) PT Raised to $94 at Wolfe Research
October 29, 2021 4:14 AM
Merck (MRK) Stock Gains on Beat-and-Raise, Sees Up To $7 Billion in Sales of COVID-19 Drug, Analysts Bullish
October 28, 2021 9:21 AM
MilliporeSigma Announces New Innovation & Capacity to Advance Next Generation Antibody-drug Conjugate (ADC) Therapies
October 28, 2021 9:00 AM
Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders
October 28, 2021 8:00 AM
Organon To Report Third Quarter Results and Host Conference Call on November 11, 2021
October 28, 2021 7:30 AM
Merck sees up to $7 billion in sales of COVID-19 drug through end of 2022
October 28, 2021 6:41 AM
Form 8-K Merck & Co., Inc. For: Oct 28
October 28, 2021 6:41 AM
Merck (MRK) Tops Q3 EPS by 20c, Offers FY Guidance
October 28, 2021 6:35 AM
Merck Announces Third-Quarter 2021 Financial Results
October 28, 2021 6:30 AM
